Clinical Trial

Global Trial in APG2575 for Patients With CLL/SLL

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-26; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2024-01-30
Trial Details
NCT Number NCT06104566
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 400 participants
Start Date 2023-12-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18